viernes, 27 de diciembre de 2024

FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder

https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-changes-labeling-transmucosal-buprenorphine-products-indicated-treat-opioid-use?utm_medium=email&utm_source=govdelivery

No hay comentarios:

Publicar un comentario